New Data Demonstrate that the Utilization of TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus over the Standard of Care Alone
A diagnosis of low-grade dysplasia in Barretts esophagus warrants expert pathology review, as these patients may have a significant risk of developing esophageal cancer.
- A diagnosis of low-grade dysplasia in Barretts esophagus warrants expert pathology review, as these patients may have a significant risk of developing esophageal cancer.
- The use of TissueCypher test results can reduce inconsistencies in management decisions for Barretts esophagus patients with low-grade dysplasia.
- In the other arm, patients were managed by the current standard of care with additional guidance from TissueCypher test results.
- The TissueCypher Barretts Esophagus test is Castles precision medicine test designed to predict future development of high-grade dysplasia (HGD) and/or esophageal cancer in patients with Barretts esophagus (BE).